✦ LIBER ✦

Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis

✍ Scribed by Cheol Woong Choi; Dae Hwan Kang; Gwang Ha Kim; Jae Sup Eum; Sun Mi Lee; Geun Am Song; Dong Uk Kim; Il Doo Kim; Mong Cho

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nafamostat Mesilate in the Prevention of

✍ Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Chan Ho Park; Yong Mock Bae; Sa 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Nafamostat Mesilate for Prevention of Po

✍ Kyo-Sang Yoo; Joon Ho Moon; Kwang Hyuk Park; Yong Woo Chung; Kyoung Oh Kim; Cheo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Nafamostat Mesilate for Prevention of Po

✍ Kyo-Sang Yoo; Won Sub Choi; Yong Woo Chung; Kyoung Oh Kim; Cheol Hee Park; Taeho 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Mo1427 The Efficacy of High Dose Nafamos

✍ Su Bum Park; Kee Tae Park; Dae Hwan Kang; Hyung Wook Kim; Cheol Woong Choi; Tae 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Outcome and Risk Factors for Post-ERCP P

✍ Youn Joo Kim; Sang Hyub Lee; Ki Young Yang; Jeong Kyun Seo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Pre-, Intra-, and Post-Procedure Risk Fa

✍ Bret T. Petersen; Robert Yacavone; Nicole Pochron; W.Scott Harmsen; Alan Zinsmei 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 55 KB